Daniel Larocque

Summary

Affiliation: GlaxoSmithKline
Location: Laval, Canada

Publications

  1. pmc Nuclear translocation controlled by alternatively spliced isoforms inactivates the QUAKING apoptotic inducer
    J Pilotte
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Genes Dev 15:845-58. 2001
  2. pmc Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen
    Gwendalyn D King
    Gene Therapeutics Research Institute, Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, California, USA
    Mol Ther 19:1793-801. 2011
  3. pmc Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology
    Daniel Larocque
    Gene Therapeutics Research Institute, Cedars Sinai Biomedical Sciences Graduate Program, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 107:14443-8. 2010
  4. doi AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity
    Arnaud M Didierlaurent
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Immunol 183:6186-97. 2009
  5. pmc The QKI-6 and QKI-7 RNA binding proteins block proliferation and promote Schwann cell myelination
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Department of Oncology and Medicine, McGill University, Montreal, Quebec, Canada
    PLoS ONE 4:e5867. 2009
  6. pmc High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity
    Gwendalyn D King
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis Bldg, Research Pavilion, Rm 5090, Los Angeles, CA 90048, USA
    J Virol 82:4680-4. 2008
  7. pmc Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain
    Weidong Xiong
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 16:343-51. 2008
  8. pmc One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 15:2154-63. 2007
  9. ncbi QUAKING KH domain proteins as regulators of glial cell fate and myelination
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Departments of Oncology and Medicine, McGill University, Montreal, Quebec, Canada
    RNA Biol 2:37-40. 2005
  10. ncbi Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression
    Kiven Erique Lukong
    Terry Fox Molecular Oncology Group and Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research and Department of Oncology, McGill University, Montreal, Quebec H3T 1E2, Canada
    J Biol Chem 280:38639-47. 2005

Collaborators

Detail Information

Publications13

  1. pmc Nuclear translocation controlled by alternatively spliced isoforms inactivates the QUAKING apoptotic inducer
    J Pilotte
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
    Genes Dev 15:845-58. 2001
    ..Moreover, our findings suggest that nuclear translocation is a novel mechanism of inactivating apoptotic inducers...
  2. pmc Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen
    Gwendalyn D King
    Gene Therapeutics Research Institute, Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, California, USA
    Mol Ther 19:1793-801. 2011
    ..These data demonstrate that the Flt3L/TK gene therapeutic approach can induce systemic immunological memory capable of recognizing a brain tumor neoantigen in a model of recurrent GBM...
  3. pmc Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology
    Daniel Larocque
    Gene Therapeutics Research Institute, Cedars Sinai Biomedical Sciences Graduate Program, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 107:14443-8. 2010
    ....
  4. doi AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity
    Arnaud M Didierlaurent
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    J Immunol 183:6186-97. 2009
    ..The transient and confined nature of these responses provides further supporting evidence for the favorable safety profile of AS04 adjuvanted vaccines...
  5. pmc The QKI-6 and QKI-7 RNA binding proteins block proliferation and promote Schwann cell myelination
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Department of Oncology and Medicine, McGill University, Montreal, Quebec, Canada
    PLoS ONE 4:e5867. 2009
    ..It was shown that QKI regulates the differentiation of oligodendrocytes, the myelinating cells of the CNS, however, little is known about the role of the QKI proteins, or RNA binding proteins in PNS myelination...
  6. pmc High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity
    Gwendalyn D King
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Davis Bldg, Research Pavilion, Rm 5090, Los Angeles, CA 90048, USA
    J Virol 82:4680-4. 2008
    ..First-generation Ad-TK failed to elicit tumor regression in this model. These results pave the way for implementing HC-Ad-TK-mediated gene therapy as a powerful adjuvant for treating GBM...
  7. pmc Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain
    Weidong Xiong
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 16:343-51. 2008
    ..This factor should be considered when developing gene therapies for neurological use...
  8. pmc One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications
    Carlos Barcia
    Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Ther 15:2154-63. 2007
    ..This study therefore indicates the utility of HC-Adv as a powerful gene therapy vector for chronic neurological disorders, even in patients who had been pre-exposed to Ad prior to gene therapy...
  9. ncbi QUAKING KH domain proteins as regulators of glial cell fate and myelination
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Departments of Oncology and Medicine, McGill University, Montreal, Quebec, Canada
    RNA Biol 2:37-40. 2005
    ..Herein, we discuss the recent advances in characterizing the QKI KH-type proteins as glial cell fate and myelin egulators...
  10. ncbi Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression
    Kiven Erique Lukong
    Terry Fox Molecular Oncology Group and Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research and Department of Oncology, McGill University, Montreal, Quebec H3T 1E2, Canada
    J Biol Chem 280:38639-47. 2005
    ..Finally, we observed that Sam68 suppressed BRK-induced cell proliferation, suggesting that Sam68 does indeed contain anti-proliferative properties that may be neutralized in breast cancer cells by phosphorylation...
  11. ncbi Protection of p27(Kip1) mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    Nat Neurosci 8:27-33. 2005
    ..Our findings demonstrate that QKI is upstream of p27(Kip1) during oligodendrocyte differentiation...
  12. ncbi Nuclear retention of MBP mRNAs in the quaking viable mice
    Daniel Larocque
    Terry Fox Molecular Oncology Group and the Bloomfield Center for Research on Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    Neuron 36:815-29. 2002
    ..MBP mRNA export defect leads to a reduction in the MBP levels and their improper cellular targeting to the periphery. Our findings suggest that QKI participates in myelination by regulating the mRNA export of key protein components...
  13. pmc The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination
    Subhash Thalappilly
    Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary, Calgary, Alberta, Canada
    PLoS ONE 6:e21065. 2011
    ....